JUN 24, 2020 1:45 PM PDT

Gilead to Test Inhalable Remdesivir Against COVID-19

WRITTEN BY: Annie Lennon

Gilead has announced that it will soon start trials for an inhalable form of Remdesivir, the first drug to receive Emergency Use Authorization by the FDA to treat COVID-19.

Currently, Remdesivir is administered to patients intravenously. This means that it can only be used in clinical settings under medical supervision.

The new, inhalable version of the treatment could change this. To be administered via nebulizer, a device commonly used to treat asthma, Gilead hopes that the more convenient treatment will be used by patients at multiple stages of infection as opposed to just severe stages demanding hospitalization. 

 “Pretty much every outpatient urgent care clinic has them. You could potentially treat somebody on the spot who has a positive test” for the coronavirus “but may or may not have symptoms.” says Dr. Angela Rasmussen, a virologist at Columbia University. 

Starting this week, healthy volunteers will be screened for Phase I trials of the inhalable treatment to check its safety. If all goes to plan, patients infected with COVID-19 may then be able to begin trials with the treatment from August. 

As antivirals are thought to be most effective during the early stages of infection, Gilead hopes that the convenience of administering the drug via nebulizer may mean it can curb the virus earlier on. 

“If you could get rid of the virus before they develop those disease symptoms, you would probably have better clinical outcomes across many patients,” says Dr. Rasmussen.

Although nebulizers generally pose few problems to patients, they have been known to irritate some people’s airways. Moreover, previous experiments for nebulizer treatments for gene therapy and insulin have both failed. There is thus no guarantee that inhalable Remdesivir will work. 

Regardless of whether it works, Gilead plans on producing two million courses of Remdesivir by the end of the year. The company has also stated that it hopes to combine the antiviral with other drugs to enhance its effects. 


Sources: Medical Xpress, New York Times, Fierce Pharma

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 16, 2020
Microbiology
A Bacterial Compound Could Become a Treatment for Parasitic Infections
JUN 16, 2020
A Bacterial Compound Could Become a Treatment for Parasitic Infections
The World Health Organization has estimated that parasitic infections cause over 48 million cases of illness and 59,000 ...
JUN 10, 2020
Drug Discovery & Development
Does Your Gut Microbiota Alter Drug Activity?
JUN 10, 2020
Does Your Gut Microbiota Alter Drug Activity?
Scientists have created a systematic way to evaluate how the microbial community in our gut influences drug behavior. Fi ...
JUN 22, 2020
Drug Discovery & Development
MDMA Has Long-Term Benefits Against PTSD
JUN 22, 2020
MDMA Has Long-Term Benefits Against PTSD
Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-t ...
JUN 25, 2020
Cell & Molecular Biology
Peptide Made by Marine Worms Can Destroy Multidrug-Resistant Bacteria
JUN 25, 2020
Peptide Made by Marine Worms Can Destroy Multidrug-Resistant Bacteria
Drug-resistant bacteria pose a serious threat to public health, and scientists have been searching for new antibiotics t ...
JUL 13, 2020
Cannabis Sciences
Over Half of CBD Products Falsely Labeled
JUL 13, 2020
Over Half of CBD Products Falsely Labeled
Tests conducted by the US Food and Drug Agency (FDA) have found that 55% of cannabidiol (CBD) products contain significa ...
JUL 17, 2020
Cancer
Tackling the Problem of Toxicity in Breast Cancer Therapy
JUL 17, 2020
Tackling the Problem of Toxicity in Breast Cancer Therapy
Chemotherapy has been one of the primary methods of cancer treatment for decades. Usually, a doctor applies a chemothera ...
Loading Comments...